Safety and Tolerability of Semaglutide: Pooled Phase 3 Data
Brigham and Women’s Hospital researchers report an integrated analysis of 18 randomized, controlled trials of semaglutide (17,639 patients), concluding its safety and tolerability are now well characterized—and similar for the subcutaneous and oral formulations.
Read More...